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There are clear evidences about the essential role of 
the immune system in the control of cancer. An 
effective response needs some steps collectively 
known as “Cancer-Immunity Cycle”. However, 
tumors have immune system evasion mechanisms that 
can break this cycle.  Thus, it is interesting to think 
about the possibility of act on the immune system to 
develop an effective anticancer response. In cancer 
treatment, immunotherapy is a promising field that 
has undergone a renaissance in recent years. 
 
Chronic lymphocytic leukemia (CLL) is the most 
common hematologic disease in Western Hemisphere 
and remains incurable, like most hematological 
malignancies. This leukemia is characterized by gradual 
accumulation of mature B-lymphocytes that co-
express CD5, CD23 and CD19. CD19 is an exclusive 
antigen of B cells, which is an important advantage for 
therapy. 
Immunotherapy for cancer has undergone a renaissance in recent years. Genetic 
modification can provide to lymphocytes specificity against tumors and thus overcome 
evasion mechanisms. The usage of CART-19 cells is a promising example with many 
encouraging results. Although there is much room for improvement, the immunotherapy 
based on engineered T cells can be a big part of the future for cancer treatment.  
Cancer antigen
presentation
Priming and activation
(APCs - T cells)
Trafficking of T cells
to the tumor
Infiltration of T cells 
into the tumors
Recognition of cancer
cells by T cells
Killing of cancer cells
Release of cancer antigens
(cancer cell death)
Lymph node
Blood
vessel
Tumor
Figure 1: Cancer Immunity cycle. The cycle can be divided into seven steps, starting with the 
release of antigens from the cancer cell and ending with the killing of cancer cells.  Abbreviations: 
APC, antigen presenting cells; CTLs, cytotoxic T lymphocytes. Adapted from reference [1]. 
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CARs have a single-chain antibody fragment (scFv), expressed in tandem 
with signaling elements derived from the T cell receptor (essentially 
CD3ζ) and co-stimulatory domains such as 4-IBB and CD28.   
CAR therapy is similar to an autologous bone marrow transplantation procedure. T cells are collected from the 
patient, cultured and genetically modified using lentiviral vectors. During this process, the patient receives 
lymphocyte-depleting chemotherapy in order to create an environment that supports the homeostatic 
expansion of T-cells and improves their effector function. Then, CART-19 cells are infused to the patient. These 
cells will recognize CD19+ tumor cells (without the need for antigen presentation by HLA), and kill them. In 
culture of T cells, CD28, CD137 (4-IBB) and CD3 co-stimulation can improve the replicative capacity.  
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•   Optimal tumor antigens and factors associated with expansion and persistence in vivo. 
•   Non-viral gene transfer technologies è minimal T cells manipulation ex vivo. 
•   Combinatorial strategies:  ACT and agents that impact on tumor biology è high response 
•   Issues about scale, automation, commercialization and intellectual property. 
ê 
Cellular therapy,  still immature, will revolutionize cancer treatment. 
INTRODUCTION 
IMMUNOTHERAPY: ADOPTIVE CELL TRANSFER WITH CART-19 CELLS 
CONCLUSIONS 
Figure 2: Schematic structure of chimeric antigen receptors (CARs). The structures of first-, 
second- and third-generation CARs are shown. 
Figure 3: (A) Scheme of ACT procedure. (B) Scheme of lentiviral vector. Abbreviations: sinLTR, self-inactivating 
long terminal repeat; RRE, rev responsive element; P, promoter; ψ, packaging signal. 
Figure 4: Scheme of artificial antigen presenting cells 
(AAPCs) or beads for T-cell stimulation in culture. 
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an approach that may have some advantages over 
the use of retroviral vectors.12
In previous trials of chimeric antigen receptor 
T cells, objective tumor responses have been mod-
est, and in vivo proliferation of modified cells has 
not been sustained.13-15 We developed a second-
generation chimeric antigen receptor designed to 
address this limitation by incorporation of the 
CD137 (4-1BB) signaling domain, on the basis of 
our preclinical observation that this molecule 
promoted the persistence of antigen-specific and 
antigen-nonspecific chimeric antigen receptor 
T-cells.5,6 Brentjens and colleagues reported pre-
liminary results of a clinical trial of CD19-targeted 
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Figure 3. Expansion and Persistence of Chimeric Antigen Receptor T Cells In Vivo.
Genomic DNA (gDNA) was isolated from samples of the patient’s whole blood (Panel A) and bone marrow aspirates (Panel B) collected at 
serial time points before and after chimeric antigen receptor T-cell infusion and used for quantitative real-time polymerase-chain-reaction 
(PCR) analysis. As assessed on the basis of transgenic DNA and the percentage of lymphocytes expressing CAR19, the chimeric antigen 
receptor T cells expanded to levels that were more than 1000 times as high as initial engraftment levels in the peripheral blood and bone 
marrow. Peak levels of chimeric antigen receptor T cells were temporally correlated with the tumor lysis syndrome. A blood sample ob-
tained on day 0 and a bone marrow sample obtained on day −1 had no PCR signal at baseline. Flow-cytometric analysis of bone marrow 
aspirates at baseline (Panel C) shows predominant infiltration with CD19+CD5+ cells that were clonal, as assessed by means of immu-
noglobulin kappa light-chain staining, with a paucity of T cells. On day 31 after infusion, CD5+ T cells were present, and no normal or 
malignant B cells were detected. The numbers indicate the relative frequency of cells in each quadrant. Both the x axis and the y axis 
show a log10 scale. The gating strategy involved an initial gating on CD19+ and CD5+ cells in the boxes on the left, and the subsequent 
identification of immunoglobulin kappa and lambda expression on the CD19+CD5+ subset (boxes on the right).
The New England Journal of Medicine 
Downloaded from nejm.org at CRAI UNIVERSITAT DE BARCELONA on June 5, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;8 nejm.org august 25, 2011728
C
re
at
in
in
e 
(m
g/
dl
)
 U
ri
c 
A
ci
d 
(m
g/
dl
)
3.5
2.5
3.0
2.0
1.5
0.5
1.0
0.0
12
8
10
6
4
2
0
LD
H
 (
IU
/l
it
er
)
1400
1000
1200
800
600
200
400
0
0 5 10 15 20 25 30
Days after Infusion
Amp R
Bacterial
replication
origin 
Bovine GH Poly A 
R region (truncated)
U3 (truncated)
3'LTR (truncated) 
CD19 BBζ
EF-1α
RRE
Truncated
env
cPPT/CTS
Truncated gag/pol
5'LTR 
R region
pELPS 19-BB-ζ
11556 bp
WPRE
VH VL
 Human CD8α
Hinge and TM 
FMC63
scFv CD3ζ4-1BB
Creatinine 
Uric acid 
LDH 
Day –1 (baseline) Day 23 6 Mo
Axial
Before Therapy
1 Mo of Treatment
3 Mo of Treatment
Coronal
A Lentiviral Vector B Serum Creatinine, Uric Acid, and LDH
C Bone Marrow–Biopsy Specimens
D Contrast-Enhanced CT
The New England Journal of Medicine 
Downloaded from nejm.org at CRAI UNIVERSITAT DE BARCELONA on June 5, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
A"
B"
A" B"
Immunolobulin"Kappa/APC"CD5/FITC"
CD
19
/P
er
CP
/C
y5
.5
"
Im
m
un
og
lo
bu
lin
"L
am
bd
a/
PE
"Tumor lysis syndrome 
ê 
Disappears with treatment	  
!
!!!!
!!!
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;8 nejm.org august 25, 2011730
an approach that may have some advantages over 
the use of retroviral vectors.12
In previous trials of chimeric antigen receptor 
T cells, objective tumor responses have been mod-
est, and in vivo proliferation of modified cells has 
not been sustained.13-15 We developed a second-
generation chimeric antigen receptor designed to 
address this limitation by incorporation of the 
CD137 (4-1BB) signaling domain, on the basis of 
our preclinical observation that this molecule 
promoted the persistence of antigen-specific and 
antigen-nonspecific chimeric antigen receptor 
T-cells.5,6 Brentjens and colleagues reported pre-
liminary results of a clinical trial of CD19-targeted 
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Figure 3. Expansion and Persistence of Chimeric Antigen Receptor T Cells In Vivo.
Genomic DNA (gDNA) was isolated from samples of the patient’s whole blood (Panel A) and bone marrow aspirates (Panel B) collected at 
serial time points before and after chimeric antigen receptor T-cell infusion and used for quantitative real-ti e polymerase-chain-reaction 
(PCR) analysis. As assessed on the basis of transgenic DNA and the percentage of lymphocytes expressing CAR19, the chimeric antigen 
receptor T cells expanded to levels that were more than 1000 times as high as initial engraftment levels in the peripheral blood and bone 
marrow. Peak levels of chimeric antigen receptor T cells were temporally correlated with the tumor lysis syndrome. A blood sample ob-
tained on day 0 and a bone marrow sample obtained on day −1 had no PCR signal at baseline. Flow-cytometric analysis of bone marrow 
aspirates at baseline (Panel C) shows predominant infiltration with CD19+CD5+ cells that were clonal, as assessed by means of immu-
noglobulin kappa light-chain staining, with a pau ity of T cells. On day 31 after infu ion, CD5+ T cells were pr sent, and no normal or 
malignant B cells were detected. The numbers indicate the relative frequency of cells in each quadrant. Both the x axis and the y axis 
show a log10 scale. The gating strategy involved an initial gating on CD19+ and CD5+ cells in the boxes on the left, and the subsequent 
identification of immunoglobulin kappa and lambda expression on the CD19+CD5+ subset (boxes on the right).
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an approach that may have some advantages over 
the use of retroviral vectors.12
In previous trials of chimeric antigen receptor 
T cells, objective tumor responses have been mod-
est, and in vivo proliferation of modified cells has 
not been sustained.13-15 We developed a second-
generation chimeric antigen receptor designed to 
address this limitation by incorporation of the 
CD137 (4-1BB) signaling domain, on the basis of 
our preclinical observation that this molecule 
promoted the persistence of antigen-specific and 
antigen-nonspecific chimeric antigen receptor 
T-cells.5,6 Brentjens and colleagues reported pre-
liminary results of a clinical trial of CD19-targeted 
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Figure 3. Expansion and Persistence of Chimeric Antigen Receptor T Cells In Vivo.
Genomic DNA (gDNA) was isolated from samples of the patient’s whole blood (Panel A) and bone marrow aspirates (Panel B) collected at 
serial time points before and after chimeric antigen receptor T-cell infusion and used for quantitative real-time polymerase-chain-reaction 
(PCR) analysis. As assessed on the basis of transgenic DNA and the percentage of lymphocytes expressing CAR19, the chimeric antigen 
receptor T cells expanded to levels that were more than 1000 times as high as initial engraftment levels in the peripheral blood and bone 
marrow. Peak levels of chimeric antigen receptor T cells were temporally correlated with the tumor lysis syndrome. A blood sample ob-
tained on day 0 and a bone marrow sample obtained on day −1 had no PCR signa  at baseline. Flow-cytometric a alysis of bone marrow 
aspirates at baseline (Panel C) shows predominant infiltration with CD19+CD5+ cells that were clonal, as assessed by means of immu-
noglobulin kappa light-chain staining, with a paucity of T cells. On day 31 after infusion, CD5+ T cells were present, and no normal or 
malignant B cells were detected. The numbers indicate the relative frequency of cells in each quadrant. Both the x axis and the y axis 
show a log10 scale. The gating strategy involved an initial gating on CD19+ and CD5+ cells in the boxes on the left, and the subsequent 
identification of immunoglobulin kappa and lambda expression on the CD19+CD5+ subset (boxes on the right).
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Evidence of immune response: Cytokine increase + CART cells infiltration 
 
Specific imm ne response against CD19    è   Leukemia cells elimination  
Figure 5: (A)	   InducUon	   of	   the	   immune	  
response	   in	  bone	  marrow.	  The	  cytokines	  TNF-­‐
α,	   interleukin-­‐6,	   interferon-­‐γ,	   chemokine	  
CXCL9,	  and	  soluble	  interleukin-­‐2	  receptor	  were	  
measured	   in	   supernatant	   ﬂuids	   of	   marrow	  
aspirates	   at	   various	   days	   before	   and	   ajer	  
CART-­‐19	  cell	  i fusion.	  The	  increases	  in	  levels	  of	  
interleukin-­‐6,	   interferon-­‐γ,	   CXCL9,	   nd	   s luble	  
interleukin-­‐2	   receptor	   coincided	   with	   the	  
tumor	   lysis	   syndrome	   (5a),	   peak	   chimeric	  
anUgen	   rec ptor	   T-­‐cell	   inﬁltraUo ,	   and	  
eradicaUon	   f	   leukemic	   inﬁltrate	   (B).	   (B)	  Bone	  
marrow	   biopsy	   specimens	   for	   3	   days	   ajer	  
chemotherapy	  and	  23	  days	  and	  6	  months	  ajer	  
CART19-­‐cell	   infusion	   (hematoxylin	   and	   eosin).	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